Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Draft WHO Guidance Provides Two Pathways For Biosimilars

Executive Summary

Clinical trials would be required for most biosimilars under two approval scenarios that are being developed by the World Health Organization

You may also be interested in...



Biosimilars Pathway In WHO Draft Guidance Drops Dual-track Approach

A World Health Organization working group dropped the less rigorous of two approaches for regulating biosimilars from its latest draft guidelines, a positive step, according to generic drug maker Sandoz

Biosimilars Pathway In WHO Draft Guidance Drops Dual-track Approach

A World Health Organization working group dropped the less rigorous of two approaches for regulating biosimilars from its latest draft guidelines, a positive step, according to generic drug maker Sandoz

Biosimilars Guidance By WHO To Be Redrafted To Clarify Data Requirements

The World Health Organization's draft guidelines for approving biosimilars will undergo another round of revisions following their review by the WHO Expert Committee on Biological Standardization

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS050196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel